What was Dr Reddy’s Q2 net profit in FY25–26?
- Answer Field
-
The company reported a consolidated net profit of ₹1,426 crore for Q2 FY25–26.
Dr Reddy’s Laboratories posted consolidated revenue of ₹8,805 Crore in Q2 FY25–26, up 9.8% YoY and 3% QoQ. Net profit rose to ₹1,426 Crore, supported by broad-based growth across branded generics and the Nicotine Replacement Therapy portfolio.
Source: Dr Reddy’s Laboratories Ltd Unaudited Consolidated Financial Results (BSE filing) | Published on Oct 24 2025
Dr Reddy’s Laboratories Ltd announced its unaudited results for the quarter ended September 30 2025. The company delivered growth in revenue and profit despite pricing pressure in the US generic segment.
Particulars | Q2 FY26 (₹ Cr) | Q1 FY26 (₹ Cr) | Q2 FY25 (₹ Cr) |
Revenue from Operations | 8,805 | 8,545 | 8,016 |
EBITDA | 2,351 | 2,282 | 2,278 |
Profit Before Tax (PBT) | 1,835 | 1,904 | 1,916 |
Profit After Tax (PAT) | 1,426 | 1,409 | 1,341 |
Earnings Per Share (Basic) | ₹17.26 | ₹17.04 | ₹15.07 |
The Board of Directors approved the unaudited results on October 24, 2025, after a review by the Audit Committee. The meeting was held from 2:00 PM to 3:57 PM IST. No dividend was declared for the quarter.
Particulars (₹ Cr) | Q2 FY26 | Q1 FY26 | Q2 FY25 |
Revenue from Operations | 8,805 | 8,545 | 8,016 |
EBITDA | 2,351 | 2,282 | 2,278 |
Profit Before Tax (PBT) | 1,835 | 1,904 | 1,916 |
Net Profit (PAT) | 1,426 | 1,409 | 1,341 |
Earnings Per Share (Basic) | ₹17.26 | ₹17.04 | ₹15.07 |
YoY decline in margins was mainly due to lower US generic prices and one-off VAT provision costs.
Particulars | Q2 FY26 (₹ Cr) | Q2 FY25 (₹ Cr) |
Revenue from Operations | 8,805 | 8,016 |
EBITDA | 2,351 | 2,278 |
Profit After Tax | 1,426 | 1,341 |
EPS (₹) | 17.26 | 15.07 |
Segment | Q2 FY26 Revenue (₹ Cr) | Q2 FY25 Revenue (₹ Cr) |
Global Generics (incl. Biologics) | 7,849 | 7,157 |
Pharmaceutical Services & Active Ingredients (PSAI) | 1,158 | 1,103 |
Others | 1.2 | 8.9 |
Regional Break-Up (Within Global Generics)
North America: ₹3,240 Cr — price erosion in key products like Lenalidomide.
Europe: ₹1,376 Cr — boost from NRT portfolio and new launches.
India: ₹1,578 Cr — driven by new brands and higher volumes.
Emerging Markets: ₹1,654 Cr — sustained momentum in Russia and CIS regions.
The results were announced on 24 October 2025, after market hours. On the next trading session (27 October 2025), Dr Reddy’s stock opened marginally higher at around ₹1,282.70 on the NSE.
(Price data based on NSE closing figures as of Oct 27 2025.)
Dr Reddy’s reported its consolidated financial results for the quarter, with growth across all major metrics compared with the same period last year. The company recorded higher income from operations and an improvement in profit before and after tax. The financial performance captured the outcome of business activity across its product categories and operations during the quarter.
For more quarterly result updates, visit Bajaj Broking’s Quarterly Results Calendar.
No result found
The company reported a consolidated net profit of ₹1,426 crore for Q2 FY25–26.
Revenue from operations stood at ₹8,805 crore.
No. The Board did not declare any dividend for this quarter.
Revenue rose by 9.8% and net profit increased by 6.3% year-on-year.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading